Literature DB >> 25882566

Targeted therapy in advanced bladder cancer: what have we learned?

Emmet J Jordan1, Gopa Iyer2.   

Abstract

Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiogenesis; MAPK pathway; Next-generation sequencing; PI3K/Akt/mTOR pathway; Small molecule inhibitors; Targeted therapy; Urothelial carcinoma

Mesh：

Substances：

Year:  2015        PMID： 25882566      PMCID： PMC4939834          DOI： 10.1016/j.ucl.2015.01.006

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  64 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

Authors:  Andrea Necchi; Luigi Mariani; Nadia Zaffaroni; Lawrence H Schwartz; Patrizia Giannatempo; Flavio Crippa; Carlo Morosi; Rodolfo Lanocita; Teodoro Sava; Cinzia Ortega; Caterina Messina; Cosimo Sacco; Marzia Pennati; Maria G Daidone; Nicola Nicolai; Filippo De Braud; Alessandro M Gianni; Roberto Salvioni
Journal:  Lancet Oncol       Date:  2012-07-20       Impact factor: 41.316

3.  Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).

Authors:  Susanne Krege; Heidrun Rexer; Frank vom Dorp; Patrick de Geeter; Theodor Klotz; Margitte Retz; Axel Heidenreich; Michael Kühn; Joern Kamradt; Susan Feyerabend; Christian Wülfing; Stefan Zastrow; Peter Albers; Oliver Hakenberg; Jan Roigas; Martin Fenner; Hans Heinzer; Mark Schrader
Journal:  BJU Int       Date:  2014-03       Impact factor: 5.588

4.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

5.  Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

Authors:  Sara Simonetti; Rosa Russo; Giuseppe Ciancia; Vincenzo Altieri; Gaetano De Rosa; Luigi Insabato
Journal:  Int J Surg Pathol       Date:  2009-06       Impact factor: 1.271

6.  Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Authors:  Wm Kevin Kelly; Victoria M Richon; Owen O'Connor; Tracy Curley; Barbara MacGregor-Curtelli; William Tong; Mark Klang; Lawrence Schwartz; Stacie Richardson; Eddie Rosa; Marija Drobnjak; Carlos Cordon-Cordo; Judy H Chiao; Richard Rifkind; Paul A Marks; Howard Scher
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

7.  Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

Authors:  Guru Sonpavde; Weiguo Jian; Hao Liu; Meng-Fen Wu; Steven S Shen; Seth P Lerner
Journal:  Urol Oncol       Date:  2008-06-04       Impact factor: 3.498

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.

Authors:  B H Bochner; R J Cote; N Weidner; S Groshen; S C Chen; D G Skinner; P W Nichols
Journal:  J Natl Cancer Inst       Date:  1995-11-01       Impact factor: 13.506

10.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Authors:  Toni K Choueiri; Robert W Ross; Susanna Jacobus; Ulka Vaishampayan; Evan Y Yu; David I Quinn; Noah M Hahn; Thomas E Hutson; Guru Sonpavde; Stephanie C Morrissey; Geoffrey C Buckle; William Y Kim; Daniel P Petrylak; Christopher W Ryan; Mario A Eisenberger; Amir Mortazavi; Glenn J Bubley; Mary-Ellen Taplin; Jonathan E Rosenberg; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544
View more
  9 in total

Review 1.  Sleeping beauty: awakening urothelium from its slumber.

Authors:  Zarine R Balsara; Xue Li
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-25

Review 2.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 3.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

4.  Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.

Authors:  Mathilde B H Thomsen; Iver Nordentoft; Philippe Lamy; Søren Høyer; Søren Vang; Jakob Hedegaard; Michael Borre; Jørgen B Jensen; Torben F Ørntoft; Lars Dyrskjøt
Journal:  Mol Oncol       Date:  2016-08-17       Impact factor: 6.603

Review 5.  mTOR inhibitors in urinary bladder cancer.

Authors:  R Pinto-Leite; R Arantes-Rodrigues; Nuno Sousa; P A Oliveira; L Santos
Journal:  Tumour Biol       Date:  2016-05-27

6.  Microarray Expression Profiles and Bioinformatics Analyses Reveal Aberrant Circular RNAs Expression in Bladder Cancer.

Authors:  Jun Yang; Junwen Chen; Si Wu; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Onco Targets Ther       Date:  2020-10-27       Impact factor: 4.147

7.  Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.

Authors:  Chih-Hung Chiang; Jing-Gung Chung; Fei-Ting Hsu
Journal:  Environ Toxicol       Date:  2019-02-25       Impact factor: 4.119

8.  Construction of a Co-Expression Network for lncRNAs and mRNAs Related to Urothelial Carcinoma of the Bladder Progression.

Authors:  Yeqing Mao; Chao Wen; Zitong Yang
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

9.  N6-methyladenosine-related single-nucleotide polymorphism analyses identify oncogene RNFT2 in bladder cancer.

Authors:  Jiancheng Lv; Qiang Song; Kexin Bai; Jie Han; Hao Yu; Kai Li; Juntao Zhuang; Xiao Yang; Haiwei Yang; Qiang Lu
Journal:  Cancer Cell Int       Date:  2022-10-05       Impact factor: 6.429
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.